A clinical trial evaluating decitabine together with either PDR001 (anti-PD-1 mAb), MBG453 (anti-TIM-3 mAb) or the combination of PDR001 and MBG453 (NCT03066648) is currently recruiting patients with AML who are R/R or not eligible for curative therapy, as well as high-risk MDS patients (Table 6). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.